Back to Search
Start Over
A Cre Driver Line for Genetic Targeting of Kappa Opioid Receptor Expressing Cells.
- Source :
-
ENeuro [eNeuro] 2023 Jul 13; Vol. 10 (7). Date of Electronic Publication: 2023 Jul 13 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Here we describe the generation and characterization of a Cre knock-in mouse line that harbors a Cre insertion in the 3'UTR of the κ opioid receptor gene ( Oprk1 ) locus and provides genetic access to populations of κ opioid receptor (KOR)-expressing neurons throughout the brain. Using a combination of techniques including RNA in situ hybridization and immunohistochemistry, we report that Cre is expressed with high fidelity in KOR-expressing cells throughout the brain in this mouse line. We also provide evidence that Cre insertion does not alter basal KOR function. Baseline anxiety-like behaviors and nociceptive thresholds are unaltered in Oprk1-Cre mice. Chemogenetic activation of KOR-expressing cells in the basolateral amygdala (BLA <superscript>KOR</superscript> cells) resulted in several sex-specific effects on anxiety-like and aversive behaviors. Activation led to decreased anxiety-like behavior on the elevated plus maze and increased sociability in female but not in male Oprk1-Cre mice. Activation of BLA <superscript>KOR</superscript> cells also attenuated KOR agonist-induced conditioned place aversion (CPA) in male Oprk1-Cre mice. Overall, these results suggest a potential role for BLA <superscript>KOR</superscript> cells in regulating anxiety-like behaviors and KOR-agonist mediated CPA. In summary, these results provide evidence for the utility of the newly generated Oprk1-Cre mice in assessing localization, anatomy, and function of KOR circuits throughout the brain.<br /> (Copyright © 2023 Paliarin et al.)
Details
- Language :
- English
- ISSN :
- 2373-2822
- Volume :
- 10
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- ENeuro
- Publication Type :
- Academic Journal
- Accession number :
- 37364995
- Full Text :
- https://doi.org/10.1523/ENEURO.0043-23.2023